- Report
- January 2026
- 183 Pages
Global
From €3458EUR$3,939USD£2,992GBP
- Report
- January 2026
- 195 Pages
Global
From €3458EUR$3,939USD£2,992GBP
- Report
- January 2026
- 188 Pages
Global
From €3458EUR$3,939USD£2,992GBP
- Report
- February 2025
- 100 Pages
Global
From €5223EUR$5,950USD£4,519GBP
- Report
- February 2025
- 120 Pages
Global
From €5223EUR$5,950USD£4,519GBP
- Report
- July 2025
- 218 Pages
Global
From €2195EUR$2,500USD£1,899GBP
- Report
- January 2026
Global
From €4302EUR$4,900USD£3,722GBP
- Report
- October 2025
Global
From €4302EUR$4,900USD£3,722GBP
- Report
- July 2025
Global
From €4302EUR$4,900USD£3,722GBP
- Report
- May 2025
- 100 Pages
Global
From €4302EUR$4,900USD£3,722GBP
- Report
- September 2025
- 250 Pages
Global
From €3942EUR$4,490USD£3,410GBP
- Report
- September 2025
- 250 Pages
Global
From €3942EUR$4,490USD£3,410GBP
- Report
- September 2025
- 250 Pages
Global
From €3942EUR$4,490USD£3,410GBP
- Report
- September 2025
- 250 Pages
Global
From €3942EUR$4,490USD£3,410GBP
- Report
- April 2025
- 200 Pages
Global
From €3942EUR$4,490USD£3,410GBP
- Report
- February 2026
- 181 Pages
Global
From €5136EUR$5,850USD£4,443GBP
- Report
- February 2026
- 365 Pages
Global
From €5136EUR$5,850USD£4,443GBP
- Report
- February 2026
- 378 Pages
Global
From €5136EUR$5,850USD£4,443GBP
- Report
- February 2026
- 267 Pages
Global
From €5136EUR$5,850USD£4,443GBP
- Report
- February 2026
- 180 Pages
Global
From €5136EUR$5,850USD£4,443GBP

T Cell Therapies are a type of biotechnology that involves the use of a patient's own T cells to treat diseases. T cells are a type of white blood cell that play a key role in the body's immune system. T Cell Therapies involve the extraction of T cells from a patient, engineering them to recognize and attack specific targets, and then reintroducing them into the patient's body. This type of therapy has been used to treat a variety of cancers, including leukemia, lymphoma, and multiple myeloma. It has also been used to treat autoimmune diseases, such as rheumatoid arthritis and Crohn's disease.
T Cell Therapies are a rapidly growing field of biotechnology, with many companies investing in research and development. Companies such as Kite Pharma, Juno Therapeutics, and Novartis are leading the way in developing and commercializing T Cell Therapies. Other companies, such as Gilead Sciences, Celgene, and Regeneron, are also investing in the field. Show Less Read more